Executive Management
Senior Vice Presidents
Vice Presidents
Scientific Advisors
Board of Directors

Executive Management

Robert J. Capetola, Ph.D.
President and Chief Executive Officer
View Bio

John G. Cooper
Executive Vice President, Chief Financial Officer
View Bio

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel
View Bio

Senior Vice Presidents

Kathryn Cole
Senior Vice President, Human Resources
View Bio

Charles F. Katzer
Senior Vice President, Manufacturing Operations
View Bio

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development
View Bio

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer
View Bio

Vice Presidents

Russell G. Clayton, D.O.
Vice President, Worldwide Clinical Research and Development
View Bio

Cynthia Davis
Vice President, Special Business Projects
View Bio

Thomas Hofmann, MD, Ph.D.
Vice President, New Product Development
View Bio

Marjorie Hurley, Pharm.D.
Vice President, Regulatory Affairs
View Bio

Mark E. Johnson, Ph.D.
Vice President, Pharmaceutical Development
View Bio

Gerald J. Orehostky
Vice President, Quality Operations
View Bio

Scientific Advisors

Charles G. Cochrane, M.D.
Founder and Professor of Immunology
The Scripps Research Institute

T. Allen Merritt, M.D.
Professor of Pediatrics
St. Charles Medical Center

Fernando R. Moya, M.D.
Director of  Neonatology
Coastal Area Health Education Center

Board of Directors

Herbert H. McDade, Jr. (Chairman)
Chairman, Access Pharmaceuticals, Inc.
Former President of Revlon Health Care and Armour Pharmaceutical Company

W. Thomas Amick
Former Johnson & Johnson Senior Executive

Robert J. Capetola, Ph.D.
President & Chief Executive Officer, Discovery Laboratories, Inc.

Antonio Esteve, Ph.D.
President, Laboratorios del Dr. Esteve

Max Link, Ph.D.
Chairman, Centerpulse, Ltd.
Former Chief Executive Officer of Sandoz Pharma, Ltd.

Marvin E. Rosenthale, Ph.D.
Former President & Chief Executive Officer of Allergan Ligand Retinoid Therapeutics, Inc.

Bio

Robert J. Capetola, Ph.D. — President, Chief Executive Officer, and a Director of Discovery Labs. Dr. Capetola has over 25 years of experience in the pharmaceutical and biotechnology industry, managing teams that developed several important drugs to commercialization, including erythropoietin, Retin-A, Suprol, Floxin, Suprane, oral contraceptives, inhaled nitric oxide and Revex. Dr. Capetola was employed for 17 years at Johnson & Johnson, starting as a drug discovery scientist and rising to the position of Senior Worldwide Director of Experimental Therapeutics. After Johnson & Johnson, Dr. Capetola joined Ohmeda Pharmaceuticals, a division of the BOC Group, as Vice President of Research and Development, while also serving as the President and Board Director of Delta Biotechnology, a UK subsidiary of Ohmeda. In late 1996, Dr. Capetola founded Acute Therapeutics, Inc., a company focused on humanized lung surfactant technology, acquired via an exclusive sub-license from Johnson & Johnson. One year later, Dr. Capetola merged his company with Discovery Laboratories, and began to focus the business on developing precision-engineered surfactants for a wide array of respiratory indications. Dr. Capetola received his B.S. from the Philadelphia College of Pharmacy & Science and his Ph.D. in Pharmacology from Hahnemann Medical College.

John G. Cooper — Executive Vice President and Chief Financial Officer, is responsible for all of the company’s financial and investor relations matters. Mr. Cooper has extensive experience in managing the needs of emerging growth companies including public and private equity financings, investor relations, strategic alliances, mergers and acquisitions, strategic and financial planning, and development of financial management and accounting systems for international operations. Previously to Discovery, Mr. Cooper held several senior financial positions including Chief Financial Officer at Mobility Technologies, Inc., a venture capital backed wireless technology company, Chief Financial Officer at Taratec Development Corporation, a venture capital backed provider of information technology solutions to the life sciences industry, Senior Vice President and Chief Financial Officer of Chrysalis International Corporation, a public company (ultimately acquired by MDS Pharmaceuticals, Inc.) providing drug development services to the life sciences industry, and Senior Vice President and Chief Financial Officer of DNX Corporation, a public biotechnology company, where Mr. Cooper managed its initial public offering in 1991. Prior to DNX, Mr. Cooper was Director, Finance and Controller of ENI Diagnostics (a public life sciences company acquired by Pharmacia in 1989). He also served as general manager and member of the board of directors for ENI's operating subsidiaries. Mr. Cooper is a certified public accountant and received his B.S. in Commerce from Rider University.

David L. Lopez, C.P.A., Esq. — Executive Vice President and General Counsel, is responsible for all legal affairs of the company. Mr. Lopez also serves as the Company’s Chief Compliance Officer overseeing its compliance committee. He has extensive experience in corporate and securities law, corporate finance, and tax and accounting matters. Previously to Discovery, Mr. Lopez served as Senior Corporate Attorney at the Manhattan law firm of Roberts, Sheridan & Kotel. Prior to that, Mr. Lopez served as a Legal Research Specialist with the Securities and Exchange Commission. He has held increasingly senior corporate finance, tax and accounting related positions with Drexel Burnham Lambert, Price Waterhouse and Deloitte, Haskins & Sells. Mr. Lopez holds a B.S. in Economics and Accounting from Fairleigh Dickinson University and a J.D. from St. John's University School of Law.

Kathryn Cole — Senior Vice President, Human Resources, is responsible for the implementation and oversight of all employee related matters, including recruitment, policies and procedures, total compensation and training. Ms. Cole has over 16 years of Human Resources experience, and most recently served as Vice President, Human Resources for Savient Pharmaceuticals Inc., a publicly-traded specialty pharmaceutical company in East Brunswick, NJ, with responsibility for creating and implementing the HR strategy for the Corporate office, Commercial Operations, and its subsidiary, Rosemont Pharmaceuticals, LTD. of Leeds, UK. Ms. Cole has also held various HR management positions with companies such as Cytogen Corporation, EpiGenesis Pharmaceuticals, and the Prudential Insurance Company of America. Ms. Cole received her undergraduate degree in Communication from Douglass College and her Master of Science degree in Industrial Relations and Human Resources from the Rutgers University School of Management and Labor Relations.

Charles F. Katzer — Senior Vice President, Manufacturing Operations, is responsible for the leadership and management of all manufacturing and global distribution of the Company’s Surfactant Replacement Therapy products. Mr. Katzer has extensive expertise in the sterile manufacture of liquids, injectables and aerosol dosage forms, product and process development, and process validation. Previously, Mr. Katzer was Vice President of Manufacturing at Medimmune Vaccines, Inc. where he was responsible for the overall leadership of worldwide vaccine manufacturing operations, including bulk virus manufacturing, formulation, filling, packaging and distribution. While at Medimmune, Mr. Katzer was instrumental in the organizational and technical transition from contract manufacturing to company managed operations. Prior to that, Mr. Katzer was Vice President of Pharmaceutical Operations at US Bioscience, where he managed regulatory cGMP inspections of European and United States operating facilities. Earlier in his career, Mr. Katzer held senior operating positions at Rhone Poulenc Rorer Pharmaceuticals. Mr. Katzer received his B.S. degree from the University of Wisconsin.

Thomas F. Miller, Ph.D., MBA — Senior Vice President, Commercialization and Corporate Development, is responsible for directing the commercial strategy for the Company’s SRT pipeline including Surfaxin® and Aerosurf™ life cycle as well as other novel SRT formulations. Dr. Miller initially joined Discovery in August 2004 as Vice President, Worldwide Marketing. He brings with him over 14 years of relevant experience which includes multiple leadership assignments at global pharmaceutical companies. Prior to joining Discovery, Dr. Miller served as the Director of Global Biologics Strategic Marketing at Centocor, a Johnson & Johnson biotechnology company, where he was responsible for the development of global business strategy for emerging, niche-market products. Previously, he held commercial and scientifically-related positions of increasing responsibility at Pharmacia, BASF Pharma, and Pfizer. Dr. Miller holds a B.S. Degree in Biology from Fairfield University, a MBA degree from Fairleigh Dickinson University and a Ph.D. in Cardio-respiratory physiology from Temple University School of Medicine, where his research focus was respiratory insufficiency and critical care intervention in neonates.

Robert Segal, M.D., F.A.C.P. — Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer, is responsible for oversight of Medical Affairs as well as scientific programs and strategies at Discovery. Dr. Segal has extensive experience in clinical research and development, and bringing drugs to market. Prior to Discovery, Dr. Segal served as Director, Cardiovascular Clinical Research at Merck Research Laboratories. Dr. Segal received his medical degree from the University of Pretoria Medical School, South Africa. He is a Diplomat of the American Board of Internal Medicine with sub-specialty certification in nephrology and is a Fellow of the American College of Physicians. He completed his internship and residency in Medicine at Sinai Hospital, Baltimore, and clinical postdoctoral fellowships in General Medicine at The Johns Hopkins Hospital and Nephrology at UCLA, as well as a research fellowship in Molecular Biology at UCLA. Prior to Merck, Dr. Segal was an Assistant Professor of Medicine in the Division of Nephrology at UCLA School of Medicine and served as an intern advisor to the Biotechnology Program at Northwestern University.

Russell G. Clayton, D.O. — Vice President, Worldwide Clinical Research and Development, is responsible for the strategic and operational management of the Medical Affairs activities for the Company's pipeline of Surfactant Replacement Therapies (SRT). Dr. Clayton brings 17 years of extensive scientific and medical experiences in the field of pulmonary and pediatric medicine. Prior to joining Discovery, Dr. Clayton served as a Director of International Regulatory Affairs, and most recently as a Regional Medical Director, Medical and Scientific Affairs at Merck & Company. Previously, Dr. Clayton served as Attending Pulmonologist at both the Children's Hospital of Philadelphia (CHOP) and St. Christopher's Hospital for Children in Philadelphia. While at CHOP, Dr. Clayton was Director of the Asthma Program for the Division of Pulmonary Medicine and Associate Director for the Cystic Fibrosis Center. Dr. Clayton also served as Assistant Professor of Pediatrics at Temple University School of Medicine and the University of Pennsylvania School of Medicine. He has given over 100 invited presentations, both national and international, and has authored articles and chapters on a variety of topics in pediatric lung disease. Dr. Clayton received his B.A. degree in Biology from LaSalle College and his medical degree from the Philadelphia College of Osteopathic Medicine.

Cynthia Davis — Vice President, Special Business Projects of Discovery.  Previously, Ms. Davis served as Controller of Discovery since 1998.  Prior to Discovery, she has served as Controller of Acute Therapeutics, Inc. from 1996 until 1998.  She has held administrative management positions with ERD Environmental Group from September 1991 until September 1996.  Ms. Davis received her A.A. degree from the Lansdale School of Business in May 1989.

Thomas Hofmann, MD, Ph.D. — Vice President, New Product Development, is responsible for the management of the Company's SRT clinical programs. Dr. Hofmann brings 16 years of experience in pediatrics and pulmonary medicine, including managing clinical trials for European and U.S. biopharmaceutical companies. Most recently, Dr. Hofmann held the position of Senior Medical Director at Corus Pharma Inc. and was a co-founder. At Corus, he was responsible for several late stage clinical development programs in respiratory and critical care medicine with a strong focus on Cystic Fibrosis, Asthma and Sleep Apnea. Prior to that, Dr. Hofmann was the Medical Director of Pulmopharm GmbH (acquired by Chiron) where he provided a significant contribution in the development and German approval of inhaled Tobramycin for Cystic Fibrosis. Dr. Hofmann has an extensive academic background and is a recognized scientist in the field of aerosol science and pulmonology, with a focus on Cystic Fibrosis. Dr. Hofmann received his Medical Degree and PhD in Electrophysiology from JLU Giessen in Germany and conducted postdoctoral research at the Cystic Fibrosis Center, University of North Carolina.

Marjorie Hurley, Pharm.D. — Vice President, Regulatory Affairs, is responsible for regulatory affairs, clinical compliance and drug safety surveillance. Dr. Hurley has over 20 years of regulatory and project management experience in the biotechnology and pharmaceutical industry. Most recently, Dr. Hurley served as Vice President, Regulatory Affairs for Neose Technologies, Inc. At Neose, Dr. Hurley managed the strategy and execution of interactions with the FDA, as well as the quality assurance and project management functions. Prior to Neose, Dr. Hurley served as Assistant Director, Regulatory Sciences at Cytogen Corporation. While at Cytogen, Dr. Hurley was responsible for regulatory submissions, clinical compliance and project management functions. She served as the Company spokesperson with the FDA and European partner on all aspects of the regulatory process. Marjorie received her Pharm.D. and B.S. in Pharmacy from the University of Michigan.

Mark E. Johnson, Ph.D. — Vice President, Pharmaceutical Development, is responsible for all pharmaceutical development and pre-clinical research for the company, including device development for the aerosol program, manufacturing process development, as well as research activities related to Surfaxin and the product pipeline. Dr. Johnson brings over 16 years of research and development experience in medical devices, process development, drug delivery and complex formulations of both small and large molecules. Prior to Discovery, Dr. Johnson held leadership positions at Corixa on a number of Clinical and Preclinical programs utilizing proteins, peptides, advanced delivery systems, and gene therapy. Dr. Johnson previously consulted at Sontra Medical and provided technical expertise to Eastman Kodak as well as authored an extensive list of patents and publications. Dr. Johnson received his Ph.D. in Chemical Engineering and his M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology, and his B.S. in Chemical Engineering from the University of California, Davis.

Gerald J. Orehostky — Vice President, Quality Operations, is responsible for the development and enhancement of GMP quality policies and systems to promote, facilitate and assure sustainable compliance with all regulatory standards. Mr. Orehostky brings with him over 19 years of diverse technical and regulatory compliance experience with global pharmaceutical, biopharmaceutical and medical device companies. Mr. Orehostky has significant leadership experience in managing global quality systems for domestic and international drug development programs and manufacturing operations as well as directing United States and European regulatory inspection activities. He has successfully developed and directed continuous improvement programs resulting in achievement of sustainable regulatory compliance. He most recently served as Executive Director of Quality Assurance and Regulatory Affairs at Palatin Technologies, Inc. and previously as Director, Worldwide Quality Services at Schering-Plough, Inc. Mr. Orehostky received his B.A. degree in Natural Science and Mathematics from Thomas Edison State College and has obtained his Quality Engineer Certification.